Ann Mohrbacher

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma

Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher et al. · Cancer · 2006 · 131 citations

Pharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia

Dan Douer, Ibrahim Aldoss, Matthew A. Lunning et al. · Journal of Clinical Oncology · 2014 · 119 citations · Full text

Toxicity profile of repeated doses of <scp>PEG</scp>‐asparaginase incorporated into a pediatric‐type regimen for adult acute lymphoblastic leukemia

Ibrahim Aldoss, Dan Douer, Carolyn E. Behrendt et al. · European Journal Of Haematology · 2015 · 83 citations · Full text

Drug Safety, Grade Bleeding, Hematological Malignancy +14

HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia

Mei Guo, Nelson J. Chao, Jianyong Li et al. · JAMA Oncology · 2017 · 46 citations · Full text